Literature DB >> 24750439

Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products.

John D Johnston1, Peter Feldschreiber.   

Abstract

Current European pharmaceutical legislation is not adequate to meet advances in science and technologies that will lead to rapid development of custom-made medicines. Using existing legislation for custom-made medical devices as a template and anti-sense oligonucleotides as model medicinal products, we propose new European pharmaceutical legislation to permit timely access to custom-made anti-sense oligonucleotide medicinal products. The proposals may be more widely applicable to other medicinal products.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  Europe; RNA; anti-sense oligonucleotide; custom-made medicine; personalized medicine; pharmaceutical regulation

Mesh:

Substances:

Year:  2014        PMID: 24750439      PMCID: PMC4093919          DOI: 10.1111/bcp.12250

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

Review 2.  Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines.

Authors:  John D Johnston; Peter Feldschreiber
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

Review 3.  Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.

Authors:  Christophe Pichavant; Annemieke Aartsma-Rus; Paula R Clemens; Kay E Davies; George Dickson; Shin'ichi Takeda; Steve D Wilton; Jon A Wolff; Christine I Wooddell; Xiao Xiao; Jacques P Tremblay
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

  3 in total
  3 in total

1.  The licence for a custom-made medicinal product is an adaptive licence.

Authors:  John D Johnston
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

2.  Phage Therapy Regulation: From Night to Dawn.

Authors:  Alan Fauconnier
Journal:  Viruses       Date:  2019-04-17       Impact factor: 5.048

3.  From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.

Authors:  H-G Eichler; L G Baird; R Barker; B Bloechl-Daum; F Børlum-Kristensen; J Brown; R Chua; S Del Signore; U Dugan; J Ferguson; S Garner; W Goettsch; J Haigh; P Honig; A Hoos; P Huckle; T Kondo; Y Le Cam; H Leufkens; R Lim; C Longson; M Lumpkin; J Maraganore; B O'Rourke; K Oye; E Pezalla; F Pignatti; J Raine; G Rasi; T Salmonson; D Samaha; S Schneeweiss; P D Siviero; M Skinner; J R Teagarden; T Tominaga; M R Trusheim; S Tunis; T F Unger; S Vamvakas; G Hirsch
Journal:  Clin Pharmacol Ther       Date:  2015-02-04       Impact factor: 6.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.